Pfizer is licensing an AI startup's drug discovery software to speed up antibody design
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
๐บ๐ธ ๋ฏธ๊ตญ ยท IT/๊ธฐ์ ยท "UNDISCLOSED" ยท ์ด 3๊ฑด
ํํฐ ๋ณด๊ธฐํ์ฌ ์ง์
48.8
0 = ๋ถ์ ์ฐ์ธ
50 = ์ค๋ฆฝ
100 = ๊ธ์ ์ฐ์ธ
์ต๊ทผ 7์ผ ๊ธฐ์ค 10,776๊ฑด์ ๋ถ์ํ ๊ฒฐ๊ณผ, ๋ด์ค ์ฌ๋ฆฌ์ง์๋ 48.8(๊ท ํ)์ ๋๋ค. ๊ธ์ 1,038๊ฑด(9.6%)ยท์ค๋ฆฝ 7,762๊ฑด(72.0%)ยท๋ถ์ 1,976๊ฑด(18.3%)์ด๋ฉฐ, ์ค๋ฆฝ ๋น์ค์ด ๋๋ ทํ๊ฒ ๋์ต๋๋ค. ์ฑํฅ ์ง์๋ ์ข ํฉ 23.1(๋ณด์ ๊ฒฝํฅ)์ ๋๋ค.
Pfizer will gain early access to Chai-3, a previously undisclosed model that doubles the antibody design success rate of its predecessor
Sellers of products with names like Boner Bears and DTF have voluntarily recalled their products after testing positive for the active ingredients in Viagra and Cialis.
Undisclosed addition in jqwik instructed AI coding agents to delete app output.